Northwest Biotherapeutics

Northwest Biotherapeutics initiates phase I/II trial

Friday, June 14, 2013 01:38 PM

Northwest Biotherapeutics, a developer of non-toxic DCVax personalized immune therapies for solid tumor cancers, has announced  its 60-patient, phase I/II clinical trial of DCVax-Direct for all inoperable solid tumor cancers has been initiated at The University of Texas MD Anderson Cancer Center.

More... »

Northwest Bio collaborates with U.K. cancer institutions for DCVaxR-Direct trial

Wednesday, November 7, 2012 11:51 AM

Northwest Biotherapeutics, a Bethesda, Md.-based biotechnology company developing DCVax personalized immune therapies for cancer, has initiated a collaboration with U.K.-based cancer institutions Sarah Cannon Research U.K. and Leaders in Oncology Care (LOC) on a phase I/II trial with DCVax-Direct for metastatic colon cancer. 

More... »

NW Bio appoints vet Rosskamp as CEO of German subsidiary

Friday, September 21, 2012 01:24 PM

Northwest Biotherapeutics, a biotech developing DCVaxR personalized immune therapies for cancer, has appointed former pharmaceutical industry executive Dr. Gunter Rosskamp as the CEO of the company's German subsidiary, Northwest Biotherapeutics, Gmbh.

More... »

Northwest Bio gets OK for phase III brain cancer trial in the U.K.

Friday, August 24, 2012 09:00 AM

Northwest Biotherapeutics, a Bethesda, Md.-based biotech, has received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) of the U.K. to proceed with the company's 300-patient phase III clinical trial of DCVax-L immune therapy for Glioblastoma multiforme brain cancer (GBM).

More... »

NW Bio opens 30 trial sites ahead of schedule

Monday, February 27, 2012 09:50 AM

Northwest Biotherapeutics (NW Bio) now has 30 clinical trial sites open and recruiting across the U.S. in its ongoing phase II clinical trial of DCVaxR-L immune therapy for Glioblastoma multiforme (GBM), the most lethal form of brain cancer. 

More... »

NWBT expands clinical sites in ongoing brain cancer trial

Thursday, August 4, 2011 11:36 AM

Northwest Biotherapeutics has expanded its number of clinical trial sites, and now has 12 sites across the U.S. open and active, where patients can enroll in the ongoing clinical trial of DCVax immune therapy for Glioblastoma multiforme (GBM), the most lethal form of brain cancer. The company also reported that a substantial number of additional sites are in progress. With the 12 sites already open and active, and others in progress, the company is on track to fulfill its prior projection that it will have 15 sites open and active in Q3 of this year.

More... »

Northwest Biotherapeutics receives $4.55 million investment

Friday, July 8, 2011 12:54 PM

Northwest Biotherapeutics has announced a $4.55 million equity investment by The Richard M. Schulze Family Foundation.  The sale of newly issued common stock of the company to the foundation follows the investment of $3 million by investment funds managed by Whitebox Advisors. The foundation has been focused for a number of years on game-changing medical research and treatment breakthroughs.  

More... »

Northwest Biotherapeutics change, expands management team

Friday, June 10, 2011 11:28 AM

Northwest Biotherapeutics (NWBT), a biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments and without toxicities, has added several executives to its management team.

More... »